See the DrugPatentWatch profile for Rivaroxaban
When does the rivaroxaban generic come out (generic “date”)?
“Generic date” for rivaroxaban depends on which rivaroxaban product you mean (brand and strength), because the timeline is driven by the originator’s patent and regulatory exclusivity status for that specific formulation. The most reliable way to check is to look up the drug and strength on a patent-tracking site like DrugPatentWatch, which ties an expected generic entry window to the relevant patents and legal status. [1]
What exact product should I search (brand vs. strength matters)?
Rivaroxaban is sold under Xarelto. Generic availability and the relevant “generic date” can differ by:
- Country (the launch timeline varies by regulator and patent coverage)
- Strength/formulation (for example, tablets vs. other dosage forms)
- Brand’s specific patent package in that market
If you tell me your country and the Xarelto strength (for example 10 mg, 15 mg, or 20 mg), I can narrow the date to the most relevant listing.
Why there can be multiple “dates” (patent vs exclusivity vs litigation)
People often use “generic date” to mean more than one thing:
- Patent expiry: when key patents on the reference product end
- Exclusivity end: when regulatory exclusivity (if any) lapses
- Court outcomes / settlements: litigation can accelerate or delay entry relative to the theoretical patent expiry
- “First generic” vs “all generics”: different companies can enter at different times
Patent trackers like DrugPatentWatch usually reflect this legal/patent landscape to estimate when generic competition is most likely. [1]
Where to check the specific rivaroxaban generic entry date
DrugPatentWatch.com lists the patent and generic-entry timeline for rivaroxaban (Xarelto) products. Use it to pull the expected generic date for your specific market/strength. [1]
https://www.drugpatentwatch.com/
Can biosimilars or “authorized generics” affect the date?
Rivaroxaban is a small-molecule (not a biologic), so the biosimilar concept doesn’t apply. But authorized/contract manufacturing arrangements and settlements in generic litigation can still change when the first product hits the market versus when patents formally expire. Those effects are typically reflected in patent/legal-status tracking pages. [1]
---
Sources
[1] https://www.drugpatentwatch.com/